Catalyst Pharmaceuticals (NASDAQ:CPRX) Releases Quarterly Earnings Results, Beats Estimates By $0.34 EPS

Catalyst Pharmaceuticals (NASDAQ:CPRX - Get Free Report) issued its quarterly earnings results on Wednesday. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.32 by $0.34, Zacks reports. The business had revenue of $141.81 million for the quarter, compared to analyst estimates of $134.20 million. Catalyst Pharmaceuticals had a return on equity of 40.79% and a net margin of 31.01%. Catalyst Pharmaceuticals updated its FY 2025 guidance to EPS.

Catalyst Pharmaceuticals Stock Performance

Catalyst Pharmaceuticals stock traded up $1.23 during midday trading on Friday, reaching $22.89. The stock had a trading volume of 1,482,299 shares, compared to its average volume of 1,279,122. Catalyst Pharmaceuticals has a 1-year low of $14.47 and a 1-year high of $24.64. The stock has a market capitalization of $2.73 billion, a P/E ratio of 19.40, a price-to-earnings-growth ratio of 3.31 and a beta of 0.80. The firm's fifty day simple moving average is $22.24 and its 200-day simple moving average is $21.44.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on CPRX shares. StockNews.com upgraded Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday. Robert W. Baird initiated coverage on shares of Catalyst Pharmaceuticals in a research report on Tuesday, February 4th. They issued an "outperform" rating and a $28.00 price target on the stock. HC Wainwright restated a "buy" rating and set a $35.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday. Baird R W upgraded shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Monday, February 3rd. Finally, Truist Financial boosted their price target on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a "buy" rating in a report on Monday, November 11th. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $32.00.

Remove Ads

Insider Activity

In related news, insider Steve Miller sold 50,000 shares of the firm's stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total value of $1,096,500.00. Following the completion of the transaction, the insider now owns 686,996 shares of the company's stock, valued at approximately $15,065,822.28. This trade represents a 6.78 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 11.00% of the stock is owned by corporate insiders.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.